Abstract: The present invention relates to stable liquid pharmaceutical compositions of curcumin or its pharmaceutically acceptable salts or its derivatives with higher curcumin concentration and improved bioavailability without the use of buffer and/or molecular aggregation inhibitor(s). In accordance with present invention the curcumin is in the solubilized form to make a stable liquid pharmaceutical composition.
Abstract: The present invention relates to a method of treating psychiatric symptoms in a subject having a NMDA receptor and a NE receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof, to the subject under conditions effective for the substance to bind to the NMDA receptor and NE receptor of the subject.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
October 18, 2016
Assignee:
Relmada Therapeutics, Inc.
Inventors:
Paolo L. Manfredi, Charles E. Inturrisi
Abstract: Methods for treating autosomal dominant polycystic kidney disease (ADPKD) are described herein. More particularly, methods described herein relate generally to administering glutaminase1 inhibitors to subjects afflicted with ADPKD. Accordingly, the use and application of compounds or agents that inhibit glutaminase1 for treating ADPKD or for use in a medicament for treating ADPKD are encompassed herein.
Abstract: Formylated xanthocillin analogs can be used in the treatment of neurodegenerative diseases. The analogs can be prepared synthetically, and at least some of the analogs can be obtained from a microorganism strain of the Penicillium chrysogenum species.
Type:
Grant
Filed:
February 6, 2013
Date of Patent:
September 27, 2016
Assignee:
NEURON BIOPHARMA, S.A.
Inventors:
Maria del Carmen Ramos Martin, Sonia Campoy Garcia, Javier Santos Burgos Muñoz, José Luis Adrio Fondevila, Javier Velasco Alvarez
Abstract: The present invention provides a method for enhancing the secretion of GLP-1 of the intestinal endocrine L-cells using a bitter compound, wherein the bitter compound is a cucurbitane-triterpenoid or allyl isothiocyanate. The bitter compound can regulate the secretion of GLP-1, thus is potentially reliable for the development of medicament or healthy victual.
Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an electrophile containing biocide, and its use for the control of microorganisms in aqueous and water-containing systems.
Abstract: The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.
Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an electrophile containing biocide, and its use for the control of microorganisms in aqueous and water-containing systems.
Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an electrophile containing biocide, and its use for the control of microorganisms in aqueous and water-containing systems.
Abstract: One embodiment of the invention is directed to a method of preventing, reducing, or eliminating at least one negative effect of oxidative damage, such as an oral disease, caused by a dental device in the mouth of a patient. Another embodiment relates to a method of preventing, reducing, or eliminating at least one negative effect of inflammation. The method may include applying topically to a soft oral tissue in the patient an oral antioxidant composition. The antioxidant composition may include between 0.0001% and 5.0% w/w or at least one antioxidant, wherein the at least one antioxidant includes a natural phytochemcial antioxidant, a flavonoid, an anthocyanidin, a dihydrochalcone, a phenylpropanoid, a chalcone, a curcuminoid, a tannin, a stilbenoid, a coumarin, a carotenoid, or a vitamin, and an orally pharmaceutically acceptable carrier. The pH of the oral antioxidant composition may be at least 5.0.
Type:
Grant
Filed:
September 28, 2012
Date of Patent:
August 23, 2016
Assignee:
Perio Sciences, LLC
Inventors:
Jan Zielinski, Thomas Russell Moon, Edward P. Allen
Abstract: Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.
Type:
Grant
Filed:
May 14, 2010
Date of Patent:
July 26, 2016
Assignee:
The General Hospital Corporation
Inventors:
Vamsi K. Mootha, Vishal Gohil, Sunil Sheth, Yuhua Ji
Abstract: (A1) A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.
Type:
Grant
Filed:
February 16, 2015
Date of Patent:
July 26, 2016
Assignees:
Oregon Health & Science University, The United States of America
Inventors:
Michael K. Riscoe, Rolf W. Winter, Jane X. Kelly, David J. Hinrichs, Martin J. Smilkstein
Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5? adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
Type:
Grant
Filed:
September 24, 2013
Date of Patent:
July 19, 2016
Assignee:
Pfizer Inc.
Inventors:
Samit Kumar Bhattacharya, Kimberly O'Keefe Cameron, Matthew Scott Dowling, David Christopher Ebner, David James Edmonds, Dilinie Prasadhini Fernando, Kevin James Filipski, Daniel Wei-Shung Kung, Esther Cheng Yin Lee, Aaron Christopher Smith, Meihua Mike Tu
Abstract: Compounds having the formula I wherein R2, X and Z as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
Type:
Grant
Filed:
August 27, 2013
Date of Patent:
July 12, 2016
Assignees:
GENETECH, INC., ARRAY BIOPHARMA INC.
Inventors:
Jim Blake, Huifen Chen, Mark Chicarelli, John Gaudino, Lewis Gazzard, Sam Kintz, Pete Mohr, Kirk Robarge, Jacob Schwarz, Aihe Zhou
Abstract: The present invention is directed to a method of screening for a therapeutic agent useful for treating pulmonary hypertension comprising: contacting an erythrocyte with a candidate therapeutic agent; and detecting a presence or absence of erythrocyte-derived adenosine triphosphate, wherein a greater erythrocyte-derived adenosine triphosphate level indicates the candidate therapeutic agent has greater activity in treating pulmonary hypertension. Additionally, the present invention is directed to methods of treating pulmonary arterial hypertension by stimulating ATP release from erythrocytes through co-administration to a subject in need thereof an amount of a PDE5 inhibitor compound, and an amount of a prostacyclin compound.
Type:
Grant
Filed:
January 10, 2013
Date of Patent:
July 12, 2016
Assignee:
United Therapeutics Corporation
Inventors:
Randy Stephen Sprague, Alan Howard Stephenson, Mary Litchfield Ellsworth, Elizabeth A. Bowles
Abstract: The present invention relates to a method of treating hypertension in a subject or patient needing treatment thereof by administering to said subject or patient at least one angiotensin II receptor blocker in combination with chlorthalidone.
Abstract: The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R1 and R2 are defined herein.
Type:
Grant
Filed:
April 3, 2014
Date of Patent:
July 5, 2016
Assignee:
Asana Biosciences, LLC
Inventors:
Aranapakam Venkatesan, Roger Astbury Smith, Subramanya Hosahalli, Vijay Potluri, Sunil Kumar Panigrahi, Vishnu Basetti, Karunasree Kunta
Abstract: The present invention relates to pharmaceutical compositions comprising polyfunctional metal phenolates that have biological applications as an anticancer adjuvant, cytoprotective antimetastatic agents and antimutagenic agents when associated with chemotherapy drugs. The present invention further relates to the use of said polyfunctional metal phenolates in the preparation of drugs for the treatment, prophylaxis or prevention of neoplasic diseases in humans and animals.
Type:
Grant
Filed:
November 11, 2009
Date of Patent:
July 5, 2016
Assignees:
UNIVERSIDADE BANDEIRANTE DE SÃO PAULO—ACADEMIA PAULISTA ANCHIETA S/C LT, FUNDAÇ
ÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO—FAPESP
Inventors:
José Agustin Quincoces Suárez, Durvanei Augusto Maria, Paulo Celso Pardi, Fernanda Faião Flores, Reginaldo Pereira Santos, Daniela Gonçales Rando
Abstract: The present invention relates to defoaming compositions comprising compounds having the formula C5H11CH(CH2CH2CH3)CH2O(CH2CH(X)O)nH (I) where X?(CH2)aCH3 where a=0 or 1 and where n=0.5-5; and one or more hydrotropes selected from the group consisting of branched or linear C4-C10 alkyl glycosides and optionally one or more anionic hydrotrope selected from the group consisting of fatty acid soaps where the acyl group contains 10-22 carbon atoms, and which could be saturated or unsaturated, linear or branched; or a sulfonate chosen from the group cumene sulfonate and xylene sulfonate, and the use of such compositions as defoaming and/or antifoaming agents. The invention also pertains to a composition comprising a) a compound C5H11CH(CH2CH2CH3)CH2O(CH2CH(X)O)nH (I) where X?(CH2)aCH3 where a=0 or 1 and n=0.
Abstract: The present disclosure provides compositions and methods for delivering nutrients to subjects requiring small-volume nutritional support, such as preterm infants. The compositions may comprise an emulsion of docosahexaenoic acid (DHA) and arachidonic acid (ARA). The nutritional compositions are useful, for example, in correcting nutritional deficiencies by increasing a subject's intake of nutrients, such as ?-3 or ?-6 long-chain polyunsaturated acids. The nutritional compositions are suitable for enteral delivery as a nutritional supplement or for oral delivery as a human milk or infant formula fortifier.
Type:
Grant
Filed:
December 9, 2010
Date of Patent:
June 28, 2016
Assignee:
Mead Johnson Nutrition Company
Inventors:
John D. Alvey, Carol Lynn Berseth, Deborah Schade, Kristin Morris